Ideaya Biosciences Inc (IDYA) USD0.0001

Sell:$32.14Buy:$32.17Price increased$0.40 (1.26%)

NASDAQ:Price increased2.18%
Market closed |
Prices delayed by at least 15 minutes
Sell:$32.14
Buy:$32.17
Change:Price increased$0.40 (1.26%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$32.14
Buy:$32.17
Change:Price increased$0.40 (1.26%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Key people

Yujiro S. Hata
President, Chief Executive Officer, Director
Joshua Bleharski
Chief Financial Officer
Andres Ruiz Briseno
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Michael A. White
Chief Scientific Officer
Darrin M. Beaupre
Chief Medical Officer
Stuart C. Dorman
Chief Commercial Officer
Terry J. Rosen
Independent Chairman of the Board
M. Garret Hampton
Independent Director
Catherine J. Mackey
Independent Director
Scott William Morrison
Independent Director
Jeffrey L. Stein
Independent Director
Click to see more

Key facts

  • Shares in issue
    87.67m
  • EPIC
    IDYA
  • ISIN
    US45166A1025
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $2.92bn
  • Employees
    131
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.